CVM CEL SCI CORP

BEARISH Impact: 7/10 8-K
Horizon weeks Filed May 13, 2026 Processed 1mo ago SEC 0001654954-26-004823
8-K material event: Items 1.01
Latest settled — T+5d
CVM ▲ +11.54% at T+5d
SHORT call ✗ call lost -11.54% · α vs SPY -12.26% · entry $1.30 → $1.45
Next anchor: T+20d due 2d ago
Currently $1.08 · +16.92% from $1.30 entry (call sign-flipped)
Entry anchored
May 13, 2026
via day open
T+1d
+10.00%
call -10.00% · α -11.23%
$1.43
settled 4w ago
T+5d
+11.54%
call -11.54% · α -12.26%
$1.45
settled 24d ago
T+20d
call — · α —
due 2d ago
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

CEL-SCI Corporation closed a best-efforts public offering of 6,000,000 shares at $1.20 per share, raising $7.2 million in gross proceeds to fund continued development of its lead candidate Multikine and for working capital. The offering represents significant dilution for a micro-cap clinical-stage biotech with no approved products, but provides near-term cash runway extension.

Key Financial Metrics

Deal Value
$7.2M

Actionable Insight

Monitor for clinical trial updates on Multikine as the primary catalyst for any upside. The 30-day lock-up on further issuance provides a temporary floor, but the high dilution and micro-cap status suggest continued volatility. Watch for any subsequent capital raises after the lock-up expires.

Key Facts

  • 6,000,000 shares sold at $1.20 per share in a best-efforts public offering
  • Gross proceeds of $7,200,000 before placement agent fees and expenses
  • Placement agent ThinkEquity received 7.0% cash fee plus up to $150,000 expense reimbursement
  • Company subject to 30-day lock-up on further equity issuance; officers/directors subject to 45-day lock-up
  • Proceeds to fund continued development of Multikine, general corporate purposes, and working capital
  • Market cap is approximately $10M, making the offering size (~$7.2M gross) highly dilutive relative to existing float

Financial Impact

Offering represents approximately 72% of pre-offering market cap in gross proceeds; significant dilution to existing shareholders

dilutioncashworking capital

Risk Factors

  • Substantial dilution to existing shareholders from the 6M share offering
  • Clinical-stage company with no approved products; Multikine has not received FDA approval
  • Limited cash runway; may require additional financing within 12 months
  • Micro-cap stock with low liquidity and high volatility

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (5 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001654954-26-004823
Document: cvm_ex991.htm0001654954-26-004823
Document: cvm_ex992.htm0001654954-26-004823
Document: 0001654954-26-004823-index-headers.html0001654954-26-004823
Document: 0001654954-26-004823-index.html0001654954-26-004823
Document: 0001654954-26-004823.txt0001654954-26-004823
4 reports for CVM
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CVM — sortable, filterable
Type Now
May 14, 2026
29d ago
8-K
BULLISH ★ 6/10
$1.43 $1.42▼ −0.70%▼ −1.66%$1.08 (−24.48%)
May 13, 2026
4w ago
8-K
BEARISH ★ 7/10
$1.30 $1.45▼ −11.54%▼ −12.26%$1.08 (+16.92%)
May 1, 2026
6w ago
S-1/A
MIXED ★ 6/10
$1.69 $1.41▼ −16.57%▼ −19.50%$1.08 (−36.09%)
Apr 17, 2026
8w ago
S-1
MIXED ★ 6/10
$3.94 $3.26▼ −17.26%▼ −18.17%$1.08 (−72.59%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (47h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access